Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Selvakumar Subbian

Showing results (91-100 of 139) with videos related to

Pageof 14
Sort By:
Plos Pathogens|September 28, 2011
Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungsSelvakumar Subbian, Liana Tsenova, Paul O'Brien, et al.
Frontiers in Pharmacology|August 28, 2020
Redox Imbalance and Oxidative DNA Damage During Isoniazid Treatment of HIV-Associated Tuberculosis: A Clinical and Translational Pharmacokinetic StudyIsaac Zentner, Hyun-Moon Back, Leonid Kagan, et al.
The American Journal of Pathology|June 28, 2011
Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathologySelvakumar Subbian, Liana Tsenova, Paul O'Brien, et al.
Journal of Clinical Medicine|July 3, 2020
Antimycobacterial Effects of Everolimus in a Human Granuloma ModelDavid Ashley, Joshua Hernandez, Ruoqiong Cao, et al.
Frontiers in Immunology|September 28, 2018
The Synergistic Effects of the Glutathione Precursor, NAC and First-Line Antibiotics in the Granulomatous Response Against <i>Mycobacterium tuberculosis</i>Garrett Teskey, Ruoqiong Cao, Hicret Islamoglu, et al.
Frontiers in Pharmacology|July 11, 2022
L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to <i>Mycobacterium tuberculosis</i> in a Diabetic Mouse ModelAbrianna Beever, Nala Kachour, James Owens, et al.
Microbial Pathogenesis|February 3, 2006
Identification of Mycobacterium marinum macrophage infection mutantsParmod K Mehta, Amit K Pandey, Selvakumar Subbian, et al.
Cell Reports|December 18, 2024
Pathogenic role for CD101-negative neutrophils in the type I interferon-mediated immunopathogenesis of tuberculosisMohd Saqib, Shreya Das, Tanvir N Nafiz, et al.
Plos One|March 3, 2011
Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected miceMi-Sun Koo, Claudia Manca, Guibin Yang, et al.
Expert Opinion on Therapeutic Targets|January 24, 2022
Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on GoliathKate C Chiang, John G Rizk, Deanna J Nelson, et al.
Pageof 14

Showing results (91-100 of 139) with videos related to

Sort By:
Pageof 14
Plos Pathogens|September 28, 2011
Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungsSelvakumar Subbian, Liana Tsenova, Paul O'Brien, et al.
Frontiers in Pharmacology|August 28, 2020
Redox Imbalance and Oxidative DNA Damage During Isoniazid Treatment of HIV-Associated Tuberculosis: A Clinical and Translational Pharmacokinetic StudyIsaac Zentner, Hyun-Moon Back, Leonid Kagan, et al.
The American Journal of Pathology|June 28, 2011
Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathologySelvakumar Subbian, Liana Tsenova, Paul O'Brien, et al.
Journal of Clinical Medicine|July 3, 2020
Antimycobacterial Effects of Everolimus in a Human Granuloma ModelDavid Ashley, Joshua Hernandez, Ruoqiong Cao, et al.
Frontiers in Immunology|September 28, 2018
The Synergistic Effects of the Glutathione Precursor, NAC and First-Line Antibiotics in the Granulomatous Response Against <i>Mycobacterium tuberculosis</i>Garrett Teskey, Ruoqiong Cao, Hicret Islamoglu, et al.
Frontiers in Pharmacology|July 11, 2022
L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to <i>Mycobacterium tuberculosis</i> in a Diabetic Mouse ModelAbrianna Beever, Nala Kachour, James Owens, et al.
Microbial Pathogenesis|February 3, 2006
Identification of Mycobacterium marinum macrophage infection mutantsParmod K Mehta, Amit K Pandey, Selvakumar Subbian, et al.
Cell Reports|December 18, 2024
Pathogenic role for CD101-negative neutrophils in the type I interferon-mediated immunopathogenesis of tuberculosisMohd Saqib, Shreya Das, Tanvir N Nafiz, et al.
Plos One|March 3, 2011
Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected miceMi-Sun Koo, Claudia Manca, Guibin Yang, et al.
Expert Opinion on Therapeutic Targets|January 24, 2022
Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on GoliathKate C Chiang, John G Rizk, Deanna J Nelson, et al.
Pageof 14